PMID- 35924249
OWN - NLM
STAT- MEDLINE
DCOM- 20220805
LR  - 20220818
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Oral Supplementation of Houttuynia cordata Extract Reduces Viremia in PRRSV-1 
      Modified-Live Virus-Vaccinated Pigs in Response to the HP-PRRSV-2 Challenge.
PG  - 929338
LID - 10.3389/fimmu.2022.929338 [doi]
LID - 929338
AB  - This study evaluated the in vitro antiviral activities and the ex vivo 
      immunomodulatory effects of Houttuynia cordata Thunb. (HC) ethanolic extracts in 
      response to porcine reproductive and respiratory syndrome virus (PRRSV). In 
      addition, this study evaluated the in vivo effects of oral supplementation of HC 
      extract on immune responses to and cross-protective efficacy of PRRSV-1 
      modified-live virus (MLV) vaccine against the highly pathogenic (HP)-PRRSV-2 
      challenge. In vitro experiments demonstrated that HC extracted in either 50%, 
      70%, or 95% ethanol (referred to as HC50, HC70, and HC95, respectively) 
      significantly interfered with PRRSV replication in MARC-145 cells. Ex vivo 
      experiments revealed that all HC extracts significantly enhanced mRNA expressions 
      of type I interferon-regulated genes, type I and II interferon (IFN), and pro- 
      and anti-inflammatory cytokines in HP-PRRSV-2-inoculated monocyte-derived 
      macrophages. An in vivo experiment included four groups of six pigs (4 weeks old; 
      n = 24). Group 1 and group 2 were vaccinated with the PRRSV-1 MLV vaccine at 0 
      dpv (day post vaccination). Group 2 also received oral administration of HC50 
      extract at 0-49 dpv. Group 3 received the PRRSV-1 MLV vaccine solvent at 0 dpv, 
      while group 4 served as strict control. Groups 1-3 were challenged intranasally 
      with HP-PRRSV-2 at 28 dpv and immune-related and clinical parameters were 
      monitored weekly until 49 dpv. Compared to group 1, group 2 demonstrated 
      significantly increased IFN regulatory factor 3 mRNA expression of PRRSV-recalled 
      peripheral blood mononuclear cells, and significantly reduced HP-PRRSV-2 viremia. 
      No difference in PRRSV-specific antibody responses, rectal temperature, clinical 
      scores, and average daily weight gain was detected. Our study reports the 
      immunomodulatory and anti-PRRSV potentials of HC extract in PRRSV-1 
      MLV-vaccinated/HP-PRRSV-2 challenged pigs.
CI  - Copyright (c) 2022 Ruansit and Charerntantanakul.
FAU - Ruansit, Wilawan
AU  - Ruansit W
AD  - Research laboratory for immunity enhancement in humans and domestic animals, 
      Program of Biotechnology, Faculty of Science, Maejo University, Chiang Mai, 
      Thailand.
FAU - Charerntantanakul, Wasin
AU  - Charerntantanakul W
AD  - Research laboratory for immunity enhancement in humans and domestic animals, 
      Program of Biotechnology, Faculty of Science, Maejo University, Chiang Mai, 
      Thailand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220718
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Viral)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Houttuynia cordata extract)
RN  - 0 (RNA, Messenger)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral
MH  - Dietary Supplements
MH  - Drugs, Chinese Herbal
MH  - *Houttuynia
MH  - Leukocytes, Mononuclear
MH  - *Porcine Reproductive and Respiratory Syndrome/prevention & control
MH  - *Porcine respiratory and reproductive syndrome virus
MH  - RNA, Messenger
MH  - Swine
MH  - Vaccines, Attenuated
MH  - *Viral Vaccines
MH  - Viremia
PMC - PMC9339630
OTO - NOTNLM
OT  - cross-protection
OT  - houttuynia cordata
OT  - interferon
OT  - modified-live virus vaccine
OT  - porcine reproductive and respiratory syndrome virus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/05 06:00
MHDA- 2022/08/06 06:00
PMCR- 2022/01/01
CRDT- 2022/08/04 02:34
PHST- 2022/04/26 00:00 [received]
PHST- 2022/06/22 00:00 [accepted]
PHST- 2022/08/04 02:34 [entrez]
PHST- 2022/08/05 06:00 [pubmed]
PHST- 2022/08/06 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.929338 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jul 18;13:929338. doi: 10.3389/fimmu.2022.929338. eCollection 
      2022.